1.Management of chronic heart failure in primary care: what evidence do we have for heart failure with preserved systolic function?
AS Ramli ; B Jackson ; CT Toh ; D Ambigga ; L Piterma
Malaysian Family Physician 2010;5(2):68-76
Chronic Heart Failure (CHF) is a debilitating illness commonly encountered in primary care. Its prevalence in developing countries is rising as a result of an ageing population, and an escalating epidemic of hypertension, type 2 diabetes and coronary heart disease. CHF can be specifically diagnosed as Heart Failure with Reduced Systolic Function (HF-RSF) or Heart Failure with Preserved Systolic Function (HF-PSF). This paper illustrates a common presentation of HF-PSF in primary
care; and critically appraises the evidence in support of its diagnosis, prognosis and management. Regardless of the specific diagnosis, long term management of CHF is intricate as it involves a complex interplay between medical, psychosocial, and behavioural factors. Hence, there is a pressing need for a multidisciplinary team management of CHF in primary care, and
this usually takes place within the broader context of an integrated chronic disease management programme. Primary care physicians are ideally suited to lead multidisciplinary teams to ensure better co-ordination, continuity and quality of care is delivered for patients with chronic conditions across time and settings. Given the rising epidemic of cardiovascular risk
factors in the Malaysian population, preventive strategies at the primary care level are likely to offer the greatest promise for reducing the growing burden of CHF.
2.Umbilical Varix Herniating Through Umbilical Defect and Mimicking Incarcerated Hernia.
Grigoriy V KLIMOVICH ; Minjeong KWON ; Jenna L KLIMOVICH ; Edward B LINEEN
Journal of Acute Care Surgery 2016;6(2):71-72
The patient is a 43-year-old male with medical history significant for severe alcoholic cirrhosis who presented with a one-month history of periumbilical pain. The patient did not have any symptoms of bowel obstruction. Physical examination revealed an umbilical defect containing an intra-abdominal structure, mimicking incarcerated umbilical hernia. Computed tomography revealed an engorged, umbilical varix 1.6 cm in diameter, herniating through the umbilical defect. No surgical intervention was offered for this patient and medical management for varix resulted in clinical resolution in three months.
Adult
;
Hernia*
;
Hernia, Umbilical
;
Humans
;
Hypertension, Portal
;
Liver Cirrhosis, Alcoholic
;
Male
;
Physical Examination
;
Varicose Veins*
3.Seroprevalence of three influenza A viruses (H1N1, H3N2, and H3N8) in pet dogs presented to a veterinary hospital in Ohio.
Hyesun JANG ; Yasmine K. JACKSON ; Joshua B. DANIELS ; Ahmed ALI ; Kyung il KANG ; Mohamed ELAISH ; Chang Won LEE
Journal of Veterinary Science 2017;18(S1):291-298
The prevalence of canine H3N8 influenza and human H1N1 and H3N2 influenza in dogs in Ohio was estimated by conducting serologic tests on 1,082 canine serum samples. In addition, risk factors, such as health status and age were examined. The prevalences of human H1N1, H3N2, and canine H3N8 influenzas were 4.0%, 2.4%, and 2.3%, respectively. Two samples were seropositive for two subtypes (H1N1 and H3N2; H1N1 and canine influenza virus [CIV] H3N8). Compared to healthy dogs, dogs with respiratory signs were 5.795 times more likely to be seropositive against H1N1 virus (p = 0.042). The prevalence of human flu infection increased with dog age and varied by serum collection month. The commercial enzyme-linked immunosorbent assay used in this study did not detect nucleoprotein-specific antibodies from many hemagglutination inhibition positive sera, which indicates a need for the development and validation of rapid tests for influenza screening in canine populations. In summary, we observed low exposure of dogs to CIV and human influenza viruses in Ohio but identified potential risk factors for consideration in future investigations. Our findings support the need for establishment of reliable diagnostic standards for serologic detection of influenza infection in canine species.
Animals
;
Antibodies
;
Cross-Sectional Studies
;
Dogs*
;
Enzyme-Linked Immunosorbent Assay
;
Hemagglutination
;
Hospitals, Animal*
;
Humans
;
Influenza A virus*
;
Influenza A Virus, H1N1 Subtype
;
Influenza, Human*
;
Mass Screening
;
Ohio*
;
Orthomyxoviridae
;
Prevalence
;
Risk Factors
;
Seroepidemiologic Studies*
;
Serologic Tests
4.TELS: A Novel Computational Framework for Identifying Motif Signatures of Transcribed Enhancers.
Dimitrios KLEFTOGIANNIS ; Haitham ASHOOR ; Vladimir B BAJIC
Genomics, Proteomics & Bioinformatics 2018;16(5):332-341
In mammalian cells, transcribed enhancers (TrEns) play important roles in the initiation of gene expression and maintenance of gene expression levels in a spatiotemporal manner. One of the most challenging questions is how the genomic characteristics of enhancers relate to enhancer activities. To date, only a limited number of enhancer sequence characteristics have been investigated, leaving space for exploring the enhancers' DNA code in a more systematic way. To address this problem, we developed a novel computational framework, Transcribed Enhancer Landscape Search (TELS), aimed at identifying predictive cell type/tissue-specific motif signatures of TrEns. As a case study, we used TELS to compile a comprehensive catalog of motif signatures for all known TrEns identified by the FANTOM5 consortium across 112 human primary cells and tissues. Our results confirm that combinations of different short motifs characterize in an optimized manner cell type/tissue-specific TrEns. Our study is the first to report combinations of motifs that maximize classification performance of TrEns exclusively transcribed in one cell type/tissue from TrEns exclusively transcribed in different cell types/tissues. Moreover, we also report 31 motif signatures predictive of enhancers' broad activity. TELS codes and material are publicly available at http://www.cbrc.kaust.edu.sa/TELS.
Enhancer Elements, Genetic
;
Genomics
;
methods
;
Humans
;
Nucleotide Motifs
;
Sequence Analysis, DNA
;
methods
;
Transcription, Genetic
5.Androgen receptor deficiency in monocytes/macrophages does not alter adiposity or glucose homeostasis in male mice.
Katya B RUBINOW ; Barbara HOUSTON ; Shari WANG ; Leela GOODSPEED ; Kayoko OGIMOTO ; Gregory J MORTON ; Christopher MCCARTY ; Robert E BRAUN ; Stephanie T PAGE
Asian Journal of Andrology 2018;20(3):276-283
Androgen deprivation in men leads to increased adiposity, but the mechanisms underlying androgen regulation of fat mass have not been fully defined. Androgen receptor (AR) is expressed in monocytes/macrophages, which are resident in key metabolic tissues and influence energy metabolism in surrounding cells. Male mice bearing a cell-specific knockout of the AR in monocytes/macrophages (M-ARKO) were generated to determine whether selective loss of androgen signaling in these cells would lead to altered body composition. Wild-type (WT) and M-ARKO mice (12-22 weeks of age, n = 12 per group) were maintained on a regular chow diet for 8 weeks and then switched to a high-fat diet for 8 additional weeks. At baseline and on both the regular chow and high-fat diets, no differences in lean mass or fat mass were observed between groups. Consistent with the absence of differential body weight or adiposity, no differences in food intake (3.0 ± 0.5 g per day for WT mice vs 2.8 ± 0.4 g per day for M-ARKO mice) or total energy expenditure (0.6 ± 0.1 Kcal h-1 for WT mice vs 0.5 ± 0.1 Kcal h-1 for M-ARKO mice) were evident between groups during high-fat feeding. Liver weight was greater in M-ARKO than that in WT mice (1.5 ± 0.1 g vs 1.3 ± 0.0 g, respectively, P = 0.02). Finally, M-ARKO mice did not exhibit impairments in glucose tolerance or insulin sensitivity relative to WT mice at any study time point. In aggregate, these findings suggest that AR signaling specifically in monocytes/macrophages does not contribute to the regulation of systemic energy balance, adiposity, or insulin sensitivity in male mice.
Adiposity/genetics*
;
Animals
;
Blood Glucose/metabolism*
;
Energy Metabolism/genetics*
;
Glucose Tolerance Test
;
Homeostasis/genetics*
;
Liver/anatomy & histology*
;
Macrophages/metabolism*
;
Male
;
Mice
;
Mice, Knockout
;
Monocytes/metabolism*
;
Organ Size
;
Receptors, Androgen/metabolism*
;
Signal Transduction
6.A programme to treat chronic hepatitis B in Kiribati: progress and challenges
Alice U. Lee ; Kathy Jackson ; Rosemary Tekoaua ; Caroline Lee ; Margaret Sue Huntley ; David C. Hilmers
Western Pacific Surveillance and Response 2020;11(3):21-25
Problem: Over 290 million people worldwide suffer from chronic hepatitis B (CHB), with the highest prevalence in the Pacific islands. Mortality attributable to this disease exceeds that from HIV, tuberculosis and malaria combined in this region.
Context: CHB is a major health problem in the Pacific island nation of Kiribati. Medical care is complicated by vast expanses of ocean separating population centres in its constituent islands. Birth-dose hepatitis B immunization rates need improvement. High rates of obesity, metabolic syndrome, and co-infection with hepatitis B and hepatitis D in Kiribati make treatment less effective. Staff allocation, training and retention are difficult. Limited infrastructure creates challenges in training, communications, laboratory testing and record-keeping.
Action: We have established a CHB treatment programme in Kiribati based on World Health Organization (WHO) guidelines and local needs. It includes direct patient care; laboratory, radiology and pharmacy support; public education; training; and data management. Thousands of individuals have been screened, and 845 hepatitis B-positive patients have had blood sent to Australia for molecular testing. Patient education pamphlets, medical training programmes and treatment protocols have been developed. Seventy-nine patients have started treatment. Regular onsite visits by technical experts are scheduled throughout the year.
Lessons learnt and discussion: This is the first national CHB treatment programme established in the Pacific islands region. Unique challenges exist in Kiribati, as they do in each nation affected by CHB. Close engagement with local partners, knowledge of the barriers involved, flexibility, advocacy, and support from WHO and volunteer technical experts are key attributes of a successful treatment programme.
7.P450-mediated dehydrotyrosine formation during WS9326 biosynthesis proceeds via dehydrogenation of a specific acylated dipeptide substrate.
Songya ZHANG ; Lin ZHANG ; Anja GREULE ; Julien TAILHADES ; Edward MARSCHALL ; Panward PRASONGPHOLCHAI ; Daniel J LENG ; Jingfan ZHANG ; Jing ZHU ; Joe A KACZMARSKI ; Ralf B SCHITTENHELM ; Oliver EINSLE ; Colin J JACKSON ; Fabrizio ALBERTI ; Andreas BECHTHOLD ; Youming ZHANG ; Manuela TOSIN ; Tong SI ; Max J CRYLE
Acta Pharmaceutica Sinica B 2023;13(8):3561-3574
WS9326A is a peptide antibiotic containing a highly unusual N-methyl-E-2-3-dehydrotyrosine (NMet-Dht) residue that is incorporated during peptide assembly on a non-ribosomal peptide synthetase (NRPS). The cytochrome P450 encoded by sas16 (P450Sas) has been shown to be essential for the formation of the alkene moiety in NMet-Dht, but the timing and mechanism of the P450Sas-mediated α,β-dehydrogenation of Dht remained unclear. Here, we show that the substrate of P450Sas is the NRPS-associated peptidyl carrier protein (PCP)-bound dipeptide intermediate (Z)-2-pent-1'-enyl-cinnamoyl-Thr-N-Me-Tyr. We demonstrate that P450Sas-mediated incorporation of the double bond follows N-methylation of the Tyr by the N-methyl transferase domain found within the NRPS, and further that P450Sas appears to be specific for substrates containing the (Z)-2-pent-1'-enyl-cinnamoyl group. A crystal structure of P450Sas reveals differences between P450Sas and other P450s involved in the modification of NRPS-associated substrates, including the substitution of the canonical active site alcohol residue with a phenylalanine (F250), which in turn is critical to P450Sas activity and WS9326A biosynthesis. Together, our results suggest that P450Sas catalyses the direct dehydrogenation of the NRPS-bound dipeptide substrate, thus expanding the repertoire of P450 enzymes that can be used to produce biologically active peptides.